Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with RRMS according to McDonald criteria 2010~* Relapse free within 30 days before Baseline data collection~* Treatment with Rebif for 6 months or more prior to informed consent~* Already using RebiSmart®2.0 + MSdialog™ for patient reported outcome (PRO) assessments (at least once prior to informed consent)~* Females of childbearing potential must be willing to use appropriate contraception for the duration of the study~* EDSS score less than (\<) 6~* Written informed consent obtained prior to any protocol-required data collection~Exclusion Criteria:~* Participation in other studies within 30 days before Baseline~* Female who is pregnant or breast feeding~* Significant psychiatric symptoms that, in the opinion of the Investigator, would impact subject ability to comply with treatment (as per standard clinical practice)~* Any contraindication for Interferon (IFN) beta-1a therapy as per Summary of Product Characteristics (SPC)~* Administration of any Multiple Sclerosis (MS) therapy, other than Rebif, within 6 months prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Relapsing-remitting Multiple Sclerosis (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).